Enoxaparin Versus Unfractionated Heparin in PCI
Information source: Triemli Hospital
ClinicalTrials.gov processed this data on August 20, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Coronary Artery Disease
Intervention: Enoxaparin i.v. (Drug); unfractionated heparin (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: Triemli Hospital Official(s) and/or principal investigator(s): osmund bertel, MD, Principal Investigator, Affiliation: Division of Cardiology Triemli Hospital Zurich
Summary
Enoxaparin 0. 75mg/kg BW is not inferior to weight adjusted unfractionated heparin as
anticoagulation for PCI
Clinical Details
Official title: Enoxaparin Versus Unfractionated Heparin in PCI
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Quadruple endpoint: death, MI, urgent TVR, major bleeding
Secondary outcome: major bleeding, minor bleeding, thrombocytopenia
Eligibility
Minimum age: N/A.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- PCI for stable ischemia or ACS
Exclusion Criteria:
- Cardiogenic shock,
- Pretreatment with study drugs,
- Lack of informed consent
Locations and Contacts
Division of Cardiology Triemli Hospital Zurich, Zurich 8063, Switzerland
Additional Information
Starting date: September 2003
Last updated: February 23, 2007
|